Vildagliptin

• CAT Number: A000934
• CAS Number: 274901-16-5
• Molecular Formula: C₁₇H₂₅N₃O₂
• Molecular Weight: 303.40
• Purity: ≥95%
• Target: Apoptosis
• Solubility: >12.1mg/mL in DMSO
• Storage: 3 years -20C powder
• IUPAC Name: (2S)-1-[2-[(3-hydroxy-1-adamantyl)amino]acetyl]pyrrolidine-2-carbonitrile
• InChI: InChI=1S/C17H25N3O2/c18-9-14-2-1-3-20(14)15(21)10-19-16-5-12-4-13(6-16)8-17(22,7-12)11-16/h12-14,19,22H,1-8,10-11H2/t12?,13?,14-,16?,17?/m0/s1
• InChIKey: SYOKIDBDQMKNDQ-XWTIBIIYSA-N
• SMILES: C1C[C@H](N(C1)C(=O)CNC23CC4CC(C2)CC(C4)(C3)O)C#N

Vildagliptin（Cat No.:A000934）is an oral antidiabetic agent that inhibits dipeptidyl peptidase-4 (DPP-4), an enzyme responsible for breaking down incretin hormones. By inhibiting DPP-4, vildagliptin increases the levels of incretins such as GLP-1 and GIP, which enhance insulin secretion and suppress glucagon release in response to meals. This dual action helps improve blood glucose control in patients with type 2 diabetes. Vildagliptin is often used in combination with other antidiabetic medications and offers a well-tolerated option with a low risk of hypoglycemia.

Overview of Clinical Research

Novartis has since withdrawn its intent to submit vildagliptin to the FDA, as of July 2008. It was approved in Feb 2008 by European Medicines Agency for use within the EU and is listed on the Australian PBS with certain restrictions.

Reference

1: Aziz KM. Fasting during Ramadan: efficacy, safety, and patient acceptability of vildagliptin in diabetic patients. Diabetes Metab Syndr Obes. 2015 Apr 16;8:207-11. doi: 10.2147/DMSO.S54683. eCollection 2015. Review. PubMed PMID: 25931826; PubMed Central PMCID: PMC4404947.
2: Forst T, Bramlage P. Vildagliptin , a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metformin. Expert Opin Pharmacother. 2014 Jun;15(9):1299-313. doi: 10.1517/14656566.2014.920009. Review. PubMed PMID: 24837407.
3: Stein SA, Lamos EM, Davis SN. Vildagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of type 2 diabetes. Expert Opin Drug Metab Toxicol. 2014 Apr;10(4):599-608. doi: 10.1517/17425255.2014.889683. Epub 2014 Feb 19. Review. PubMed PMID: 24547938.
4: Kožnarová R. [Use of vildagliptin from an internal disease specialists point of view]. Vnitr Lek. 2013 Apr;59(4):322-4. Review. Czech. PubMed PMID: 23711060.
5: Khan S, Khan S, Imran M, Pillai KK, Akhtar M, Najmi AK. Effects of pioglitazone and vildagliptin on coagulation cascade in diabetes mellitus–targeting thrombogenesis. Expert Opin Ther Targets. 2013 Jun;17(6):627-39. doi: 10.1517/14728222.2013.764991. Epub 2013 Jan 28. Review. PubMed PMID: 23356568.
6: Dejager S, Schweizer A, Foley JE. Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus. Vasc Health Risk Manag. 2012;8:339-48. doi: 10.2147/VHRM.S31758. Epub 2012 May 18. Review. PubMed PMID: 22661900; PubMed Central PMCID: PMC3363148.
7: Guarino E, Nigi L, Patti A, Fondelli C, Dotta F. Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus. Expert Opin Pharmacother. 2012 Jun;13(9):1377-84. doi: 10.1517/14656566.2012.667078. Epub 2012 Mar 7. Review. PubMed PMID: 22397507.
8: He YL. Clinical pharmacokinetics and pharmacodynamics of vildagliptin. Clin Pharmacokinet. 2012 Mar 1;51(3):147-62. doi: 10.2165/11598080-000000000-00000. Review. PubMed PMID: 22339447.
9: Cai L, Cai Y, Lu ZJ, Zhang Y, Liu P. The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials. J Clin Pharm Ther. 2012 Aug;37(4):386-98. doi: 10.1111/j.1365-2710.2011.01323.x. Epub 2011 Dec 22. Review. PubMed PMID: 22191695.
10: Kalra S. Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin in the management of type 2 diabetes. J Assoc Physicians India. 2011 Apr;59:237-45. Review. PubMed PMID: 21755761.